SCHEMBL16428841

SCHEMBL16428841

CCc1c(O)cc(=O)[nH]c1-c1ccc2c(ccn2-c2ccc(F)cc2)c1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KCNH2 Q12809 2/20 0.43
MGLL Q99685 4/20 0.38
ALDH1A1 P00352 6/20 0.38
KDM4E B2RXH2 6/20 0.38
HPGD P15428 4/20 0.38
MAPT P10636 3/20 0.38
NPC1 O15118 1/20 0.38
TSHR P16473 1/20 0.38
ALOX12 P18054 1/20 0.38
RAB9A P51151 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.38
HSD17B10 Q99714 1/20 0.38
EPHX2 P34913 1/20 0.36
GABRA2 P47869 1/20 0.34
GABRB2 P47870 1/20 0.34
CYP1A2 P05177 2/20 0.34
CYP2C9 P11712 2/20 0.34
CYP2C19 P33261 2/20 0.34
GAA P10253 1/20 0.34
MAPK1 P28482 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14745008 0.81 KCNH2 (0.39) KCNH2MGLLALDH1A1KDM4EHPGD
SCHEMBL16428628 0.79 NOX4 (0.36) KDM4EMAPTCYP1A2CYP2C9CYP2C19
SCHEMBL16428798 0.78 MEN1 (0.38) ALDH1A1KDM4EHPGDMAPTTSHR
SCHEMBL16428918 0.78 GLO1 (0.35)
SCHEMBL14746854 0.75 KDM4E (0.41) ALDH1A1KDM4EHPGDMAPTHSD17B10
SCHEMBL16428410 0.73 USP7 (0.48)
SCHEMBL14745667 0.72 MGLL (0.37) KCNH2MGLLCYP2C19CYP3A4MCHR1
SCHEMBL14745264 0.71 DHODH (0.41) MGLLALDH1A1MAPTSMN1; SMN2POLB
SCHEMBL16428430 0.70 MAPT (0.38) ALDH1A1KDM4EHPGDMAPTNPC1
SCHEMBL14757687 0.69 KIF11 (0.34) KCNH2MGLLALDH1A1MAPTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9409905-B2 Antibacterial compounds and methods for use PTC THERAPEUTICS, INC. (US) 2016-08-09 US disclosed
US-20150038437-A1 ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE PTC THERAPEUTICS, INC. (US) 2015-02-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150038437-A1 ANTIBACTERIAL COMPOUNDS AND METHODS FOR USE MRPL21, SLC11A2, CLPP KCNH2 3306/4885MGLL 340/4885ALDH1A1 3792/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.